Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence.

Blue DR, Daniels DV, Gever JR, Jett MF, O'Yang C, Tang HM, Williams TJ, Ford AP.

BJU Int. 2004 Jan;93(1):162-70.


A randomized crossover study to evaluate Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence.

Musselman DM, Ford AP, Gennevois DJ, Harbison ML, Laurent AL, Mokatrin AS, Stoltz RR, Blue DR.

BJU Int. 2004 Jan;93(1):78-83.


Synthesis, pharmacology and pharmacokinetics of 3-(4-aryl-piperazin-1-ylalkyl)-uracils as uroselective alpha1A-antagonists.

Lopez FJ, Arias L, Chan R, Clarke DE, Elworthy TR, Ford AP, Guzman A, Jaime-Figueroa S, Jasper JR, Morgans DJ Jr, Padilla F, Perez-Medrano A, Quintero C, Romero M, Sandoval L, Smith SA, Williams TJ, Blue DR.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1873-8.


Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction.

Choppin A, Blue DR, Hegde SS, Gennevois D, McKinnon SA, Mokatrin A, Bivalacqua TJ, Hellstrom WJ.

Int J Impot Res. 2001 Jun;13(3):157-61.


alpha 2A-adrenoceptors, not I1-imidazoline receptors, mediate the hypotensive effects of rilmenidine and moxonidine in conscious mice. In vivo and in vitro studies.

Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr.

Ann N Y Acad Sci. 1999 Jun 21;881:287-9. No abstract available.


In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

Williams TJ, Blue DR, Daniels DV, Davis B, Elworthy T, Gever JR, Kava MS, Morgans D, Padilla F, Tassa S, Vimont RL, Chapple CR, Chess-Williams R, Eglen RM, Clarke DE, Ford AP.

Br J Pharmacol. 1999 May;127(1):252-8.


Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.

Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr.

Br J Pharmacol. 1999 Mar;126(6):1522-30.


N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.

Elworthy TR, Ford AP, Bantle GW, Morgans DJ Jr, Ozer RS, Palmer WS, Repke DB, Romero M, Sandoval L, Sjogren EB, Talamás FX, Vazquez A, Wu H, Arredondo NF, Blue DR Jr, DeSousa A, Gross LM, Kava MS, Lesnick JD, Vimont RL, Williams TJ, Zhu QM, Pfister JR, Clarke DE.

J Med Chem. 1997 Aug 15;40(17):2674-87.


RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.

Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, Clarke DE.

Mol Pharmacol. 1996 Feb;49(2):209-15.


Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Blue DR Jr, Bonhaus DW, Ford AP, Pfister JR, Sharif NA, Shieh IA, Vimont RL, Williams TJ, Clarke DE.

Br J Pharmacol. 1995 May;115(2):283-94.


Alpha 1-adrenoceptor classification: sharpening Occam's razor.

Ford AP, Williams TJ, Blue DR, Clarke DE.

Trends Pharmacol Sci. 1994 Jun;15(6):167-70. Review. No abstract available.


Characterization of the alpha-1 adrenoceptor subtype mediating [3H]-arachidonic acid release and calcium mobilization in Madin-Darby canine kidney cells.

Blue DR Jr, Craig DA, Ransom JT, Camacho JA, Insel PA, Clarke DE.

J Pharmacol Exp Ther. 1994 Mar;268(3):1588-96.


Evidence for a noradrenergic innervation to alpha 1A-adrenoceptors in rat kidney.

Blue DR Jr, Vimont RL, Clarke DE.

Br J Pharmacol. 1992 Oct;107(2):414-7.


Antagonist characterization of atypical beta adrenoceptors in guinea pig ileum: blockade by alprenolol and dihydroalprenolol.

Blue DR, Bond RA, Adham N, Delmendo R, Michel AD, Eglen RM, Whiting RL, Clarke DE.

J Pharmacol Exp Ther. 1990 Mar;252(3):1034-42.


Supplemental Content

Support Center